Allergy Therapeutics plc (LON:AGY - Get Free Report) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 6.66 ($0.09) and traded as low as GBX 6.50 ($0.09). Allergy Therapeutics shares last traded at GBX 6.77 ($0.09), with a volume of 1,126,674 shares.
Allergy Therapeutics Stock Performance
The stock has a market cap of £358.80 million, a PE ratio of -7.04, a PEG ratio of -30.70 and a beta of 1.40. The stock has a fifty day simple moving average of GBX 6.99 and a two-hundred day simple moving average of GBX 6.69. The company has a debt-to-equity ratio of 835.48, a quick ratio of 1.48 and a current ratio of 1.63.
Allergy Therapeutics (LON:AGY - Get Free Report) last released its quarterly earnings results on Monday, March 31st. The company reported GBX (0.23) ($0.00) earnings per share for the quarter. Allergy Therapeutics had a negative return on equity of 266.59% and a negative net margin of 72.86%. Equities analysts anticipate that Allergy Therapeutics plc will post -2.56 EPS for the current fiscal year.
About Allergy Therapeutics
(
Get Free Report)
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
See Also
Before you consider Allergy Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allergy Therapeutics wasn't on the list.
While Allergy Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
